The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), significantly improving access to diabetes

The FDA has approved the first generic form of liraglutide (Victoza), a once-daily injectable for improving glycemic control in patients ages 10 and older with type 2 diabetes, used as an adjunct to diet and exercise.

The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes/weight-loss med tirzepatide is over.